• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

    12/3/21 9:11:26 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously
    Get the next $CRVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

      SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelit

      6/25/25 8:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

      SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the

      6/11/25 7:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patient

      6/4/25 7:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care